169 related articles for article (PubMed ID: 37721580)
41. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
Zhang YY; Song L; Zhao MX; Hu K
Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
[TBL] [Abstract][Full Text] [Related]
42. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
Jin P; Bai M; Liu J; Yu J; Meng X
Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
[TBL] [Abstract][Full Text] [Related]
43. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
44. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
45. Prognostic Impact of Pretreatment 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
[No Abstract] [Full Text] [Related]
46. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
[TBL] [Abstract][Full Text] [Related]
47. Deep-Learning
Capobianco N; Meignan M; Cottereau AS; Vercellino L; Sibille L; Spottiswoode B; Zuehlsdorff S; Casasnovas O; Thieblemont C; Buvat I
J Nucl Med; 2021 Jan; 62(1):30-36. PubMed ID: 32532925
[TBL] [Abstract][Full Text] [Related]
48. Tumor and bone marrow uptakes on [18F]fluorodeoxyglucose positron emission tomography/computed tomography predict prognosis in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy.
Chang CC; Cho SF; Tu HP; Lin CY; Chuang YW; Chang SM; Hsu WL; Huang YF
Medicine (Baltimore); 2017 Nov; 96(45):e8655. PubMed ID: 29137104
[TBL] [Abstract][Full Text] [Related]
49. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
50. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Value of
Albano D; Camoni L; Giubbini R; Bertagna F
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e897-e904. PubMed ID: 32703751
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL).
Xie Y; Teng Y; Jiang C; Ding C; Zhou Z
Jpn J Radiol; 2023 Jul; 41(7):777-786. PubMed ID: 36752954
[TBL] [Abstract][Full Text] [Related]
53. Value of
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
[TBL] [Abstract][Full Text] [Related]
55. Lymph node standardized uptake values at pre-treatment
Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
[TBL] [Abstract][Full Text] [Related]
56. Nomograms based on SUVmax of
Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
[TBL] [Abstract][Full Text] [Related]
57. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [
Zhang X; Chen L; Jiang H; He X; Feng L; Ni M; Ma M; Wang J; Zhang T; Wu S; Zhou R; Jin C; Zhang K; Qian W; Chen Z; Zhuo C; Zhang H; Tian M
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1298-1310. PubMed ID: 34651227
[TBL] [Abstract][Full Text] [Related]
58. Prognostic Value of
Carlier T; Frécon G; Mateus D; Rizkallah M; Kraeber-Bodéré F; Kanoun S; Blanc-Durand P; Itti E; Le Gouill S; Casasnovas RO; Bodet-Milin C; Bailly C
J Nucl Med; 2024 Jan; 65(1):156-162. PubMed ID: 37945379
[TBL] [Abstract][Full Text] [Related]
59. Prognostic Value of
Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
[TBL] [Abstract][Full Text] [Related]
60. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
